NCT05396352 Cerebellum and Autism: Regional Specialization for Social and Executive Functions
| NCT ID | NCT05396352 |
| Status | Recruiting |
| Phase | — |
| Sponsor | American University |
| Condition | Autism |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2022-01-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2022-01-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to determine the impact of neuromodulation to the cerebellum on social and executive functions in neurotypical young adults and young adults with autism.
Eligibility Criteria
Please note: This study takes place at American University and Georgetown University in Washington, DC. We do not have funds for travel and lodging available for this study, so participants should be local to the DC region. Inclusion Criteria: All participants * Aged 18-35 * Able to provide written, informed consent * NIH Toolbox age-adjusted Cognitive Function Composite standard score ≥ 85 * Native English speaker * Right-handed * Not pregnant * Able to attend all study sessions * Pass safety screening for MRI and neuromodulation (e.g. no metal in body, implanted devices, history of seizure, claustrophobia) Additional INCLUSION criteria for adults with autism Either * Prior research-reliable diagnosis of autism spectrum disorder (ASD) Or * Meet DSM-5 criteria for ASD confirmed with ADOS-2 via research-reliable clinical assessment Exclusion Criteria: Neurotypical adults * Age \<18 or \>35 * NIH Toolbox age-adjusted Cognitive Function Composite standard score \< 85 * Contraindications for MRI or neuromodulation with tDCS (e.g. metal in body, pacemaker or other implanted device, history of seizure, claustrophobia) * Current or prior history of neurological or neurodevelopmental condition or brain injury * Psychotropic medication * Pregnancy Adults with autism * Age \<18 or \>35 * Participants with a legal authorized representative * NIH Toolbox age-adjusted Cognitive Function Composite standard score \< 85 * Contraindications for MRI or neuromodulation with tDCS (e.g. metal in body, pacemaker or other implanted device, history of seizure, claustrophobia) * Pregnancy
Contact & Investigator
Kathleen Gunthert, Ph.D.
PRINCIPAL INVESTIGATOR
American University
Frequently Asked Questions
Who can join the NCT05396352 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 35 Years, studying Autism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05396352 currently recruiting?
Yes, NCT05396352 is actively recruiting participants. Contact the research team at stoodley@american.edu for enrollment information.
Where is the NCT05396352 trial being conducted?
This trial is being conducted at Washington D.C., United States.
Who is sponsoring the NCT05396352 clinical trial?
NCT05396352 is sponsored by American University. The principal investigator is Kathleen Gunthert, Ph.D. at American University. The trial plans to enroll 80 participants.